BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250414T140000
DTEND;TZID=Europe/Paris:20250414T140000
DTSTAMP:20260407T091931
CREATED:20250326T154729Z
LAST-MODIFIED:20250327T102510Z
UID:182213-1744639200-1744639200@www.bordeaux-neurocampus.fr
SUMMARY:Seminar - Kenneth L. Madsen
DESCRIPTION:Venue: Centre Broca \n\nKenneth L. Madsen \nDepartment of Neuroscience  \n University of Copenhagen  \nInvited by David Perrais (IINS) \nTitle\nA peripherally restricted PICK1 inhibitor for treatment of chronic pain \nAbstract\nKathrine L. Jensen1\,2\, Sara E. Jager2\, Carolyn M. Goddard2\, Marco Kowenicki1\, Andreas T. Sørensen1\,2\, Kenneth L. Madsen1\,2 \n1 Zyneyro\, Hørsholm\, Denmark \n2Molecular Neuropharmacology and Genetics Laboratory\, Department of Neuroscience\, University of Copenhagen\, Denmark \nWorldwide 1.5 billion people suffer from chronic pain. Whereas pain is crucial for our survival\, maladaptive pain serves no biological function\, and leads to comorbidities such as anxiety\, depression\, poor sleep\, and high prescription drug use. We have developed and characterized a bivalent lipid-conjugated peptide\, mPD5\, designed to bind to the PDZ domain of the scaffold protein PICK1 (Protein Interacting with C-kinase 1). mPD5 relieves both ongoing and evoked hypersensitivity in multiple mouse models of pain in both female and male mice. Current treatment options for chronic pain entail severe dose-limiting side effects originating from their action on the CNS. However\, we have data suggesting that the distribution of mPD5 is restricted to peripheral tissues. Clearing of brain and spinal column tissue of mice injected with labelled mPD5 in combination with mass spectrometry data of brain tissue\, spinal cord tissue\, plasma\, and CSF of mice injected with unlabelled mPD5 indicate that mPD5 is peripherally restricted. mPD5 was present in dorsal root ganglions (DRGs) and plasma\, but undetected in CSF\, spinal cord\, or brain. While PICK1 is well described in the CNS\, we lack knowledge about the role of PICK1 in the PNS. By extracting mRNA data from a publicly accessible database\, we have confirmed the presence of PICK1 along the somatosensory nociceptive pathway of both human and mouse\, including DRGs. In addition\, we have used mPD5 mimicking peptides to successfully pull down PICK1 from both spinal cord and DRG tissue from male and female humandonors\, substantiating that PICK1 is indeed a relevant therapeutic pain target in humans as well. Lastly\, other peripherally acting drugs such as botox\, lidocaine patches\, and capsaicin patches lead to impaired acute nociception. We have used a hot water tail immersion test (49 oC) and a capsaicin paw-lick test revealing normal sensory perception of mice treated with mPD5. Relieving chronic pain\, without limiting the sensitivity to potential harmful stimuli of everyday life would be a great benefit for patients. In conclusion\, mPD5 alleviates hypersensitivity through a novel mechanism offering a unique option for further investigation that could provide valuable insight into the biology of pain. \nSelected publications\n\nFadahunsi N et al. (2024) Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment. Science Advances 10:eadg2636.\nJensen KL et al. (2024) Peripherally restricted PICK1 inhibitor mPD5 ameliorates pain behaviors in murine inflammatory and neuropathic pain models. JCI Insight 9\nAndersen RC et al. (2022) Coding variants identified in patients with diabetes alter PICK1 BAR domain function in insulin granule biogenesis. J Clin Invest 132\nChristensen NR\, Pedersen CP\, Sereikaite V\, Pedersen JN\, Vistrup-Parry M\, Sørensen AT\, Otzen D\, Teilum K\, Madsen KL\, Strømgaard K (2022) Bidirectional protein–protein interactions control liquid–liquid phase separation of PSD-95 and its interaction partners. iScience 25\n\n
URL:https://www.bordeaux-neurocampus.fr/en/event/seminar-kenneth-l-madsen/
CATEGORIES:For scientists,home-event,IINS,Impromptu seminar
END:VEVENT
END:VCALENDAR